EcoDrugPlus

Map Kinase-Activated Protein Kinase 2-Like

Ensembl ID : ENSPKIG00000012021
Gene Symbol: LOC111834362
4 Cross references
230 Possible Orthologues:

Mapk Activated Protein Kinase 2

Ensembl ID : ENSPKIG00000004557
Gene Symbol: MAPKAPK2
4 Cross references
230 Possible Orthologues:

Mapk Activated Protein Kinase 5

Ensembl ID : ENSPKIG00000023236
Gene Symbol: MAPKAPK5
3 Cross references
179 Possible Orthologues:

Mapk Interacting Serine/threonine Kinase 2

Ensembl ID : ENSPKIG00000013963
Gene Symbol: MKNK2
4 Cross references
222 Possible Orthologues:

Mapk Interacting Serine/threonine Kinase 2

Ensembl ID : ENSPKIG00000016487
Gene Symbol: MKNK2
4 Cross references
222 Possible Orthologues:

Mcl1 Apoptosis Regulator, Bcl2 Family Member B

Ensembl ID : ENSPKIG00000010863
Gene Symbol: MCL1B
1 Cross references
227 Possible Orthologues:

Mdm2 Proto-Oncogene

Ensembl ID : ENSPKIG00000022554
Gene Symbol: MDM2
3 Cross references
282 Possible Orthologues:

Met Proto-Oncogene, Receptor Tyrosine Kinase

Ensembl ID : ENSPKIG00000025550
Gene Symbol: MET
3 Cross references
204 Possible Orthologues:

Mtor Associated Protein, Lst8 Homolog

Ensembl ID : ENSPKIG00000001882
Gene Symbol: MLST8
3 Cross references
202 Possible Orthologues:

Npc1 Like Intracellular Cholesterol Transporter 1

Ensembl ID : ENSPKIG00000001325
Gene Symbol: NPC1L1
4 Cross references
189 Possible Orthologues:

P2x Purinoceptor 3-Like

Ensembl ID : ENSPKIG00000015212
Gene Symbol: LOC111861068
3 Cross references
198 Possible Orthologues:

P2x Purinoceptor 3-Like

Ensembl ID : ENSPKIG00000007547
Gene Symbol: LOC111834179
3 Cross references
192 Possible Orthologues:


PREMIER has received funding from the Innovative Medicines Initiative 2 Joint Undertaking (JU) under grant agreement No 875508. The JU receives support from the EU’s Horizon 2020 research and innovation programme and the European Federation of Pharmaceutical Industries and Associations (EFPIA). The views reflect only the authors’ perspective and the JU is not responsible for any use that may be made of the information this manuscript contains. Elements of the website have been developed under projects PREMIER and the Biocenter Finland Drug Discovery and Chemical Biology network. CSC-IT is thanked for providing computational resources. Content of the website is provided without guarantee for correctness. Data has been collected and integrated from multiple public sources, for the largest: FDA, HUGO Gene Nomenclature Committee, ChEMBL, IUPHAR/BPS guide to pharmacology, Reactome, UniProt, and Ensembl. Credit is given to Ensembl for collecting species images (provided under public domain licences such as Wikimedia and NHGRI).

PREMIER has received funding from the Innovative Medicines Initiative 2 Joint Undertaking (JU) under grant agreement No 875508. The JU receives support from the EU’s Horizon 2020 research and innovation programme and the European Federation of Pharmaceutical Industries and Associations (EFPIA). The views reflect only the authors’ perspective and the JU is not responsible for any use that may be made of the information this manuscript contains.

Elements of the website have been developed under projects PREMIER and the Biocenter Finland Drug Discovery and Chemical Biology network. CSC-IT is thanked for providing computational resources. Content of the website is provided without guarantee for correctness. Data has been collected and integrated from multiple public sources, for the largest: FDA, HUGO Gene Nomenclature Committee, ChEMBL, IUPHAR/BPS guide to pharmacology, Reactome, UniProt, and Ensembl. Credit is given to Ensembl for collecting species images (provided under public domain licences such as Wikimedia and NHGRI).